Results 61 to 70 of about 3,254,927 (309)

Novel Ferritin Light Chain Gene Mutation in a Korean Patient with Neuroferritinopathy [PDF]

, 2019
ope
류철형
core   +1 more source

Regional reduction of high-energy phosphorus metabolites characterizes the cerebellar subtype of multiple system atrophy

npj Parkinson's Disease
Multiple system atrophy (MSA) is a severe neurodegenerative disorder with various underlying pathophysiological features. Mitochondrial dysfunction has been implied as a viable treatment target in patients with MSA.
Jannik Prasuhn, Christina Bodemann, Britt Ebeling, Katharina Reuther, Sinja S. Großer, Jan Uter, Julia Henkel, Henrike Hanssen, Norbert Brüggemann   +8 more
doaj   +1 more source

Comparable Botulinum Toxin Outcomes between Primary and Secondary Blepharospasm: A Retrospective Analysis

Tremor and Other Hyperkinetic Movements, 2014
Background: Blepharospasm is a focal cranial dystonia, which could be idiopathic in origin or secondary to an underlying disorder that commonly impairs quality of life.
Daniel Martinez-Ramirez, Juan C. Giugni, Erin Hastings, Aparna W. Shukla, Irene A. Malaty, Michael S. Okun, Ramon L. Rodriguez   +6 more
doaj   +1 more source

Investigating transcription factor dynamics in health and disease using FRAP

FEBS Letters, EarlyView.
FRAP analysis of GFP‐tagged transcription factors reveals how molecular mobility and target engagement change in response to drug treatment. By combining live‐cell imaging, quantitative model fitting, and statistical analysis, this approach uncovers transcription factor dynamics linked to disease mechanisms, providing a powerful framework for ...
Kannan Govindaraj, Carolina Vazquez Garzon, Jose Joaquin Velasco, Janine N. Post   +3 more
wiley   +1 more source

Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms [PDF]

, 2018
In recent years, several radiotracers that selectively bind to pathological tau proteins have been developed. Evidence is emerging that binding patterns of in vivo tau positron emission tomography (PET) studies in Alzheimer's disease (AD) patients ...
최재용, 유영훈, 조한나, 이명식, 류철형   +4 more
core   +1 more source

Deep Learning Pose Estimation for Phenotyping of Co-Occurring Hyperkinetic Movement Disorders. [PDF]

Ann Clin Transl Neurol
ABSTRACT Objective To explore whether routine outpatient video combined with deep learning‐based pose estimation and clinically interpretable kinematic features can support multi‐label phenotyping of co‐occurring hyperkinetic movement disorders (HMDs).
Cif L, Demailly D, Horvàth GA, Ortigoza Escobar JD, Dorison N, Castro Jiménez M, Hubsch CA, Wirth T, Hariz GM, Huby S, Dornadic M, Souei Z, Mushhood Ur Rehman M, Hemm S, Boulaymen M, Moraud EM, Bloch J, Vasques X.   +17 more
europepmc   +2 more sources

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Clinical Management of Movement Disorders

Movement disorders represent a heterogeneous field of Neurology that includes a wide variety of diseases. Phenomenologically, such disturbances are classically distinguished into hyperkinetic and hypokinetic disorders.

core   +1 more source

Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study [PDF]

Glucose transporter type 1 deficiency syndrome; Paroxysmal movement disorder; TriheptanoinSíndrome de deficiencia del transportador de glucosa tipo 1; Trastorno del movimiento paroxístico; TriheptanoínaSíndrome de deficiència del transportador de glucosa
Bhatia, Kailash, Desurkar, Archana, gras, domitille, boespflug-tanguy, odile, Della Marina, Adela, Toledo, Manuel, De Giorgis, Valentina   +6 more
core   +1 more source